RIN Institute
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $1.9M
Investors
- 2
About RIN Institute
Based in Japan, RIN Institute Inc.RIN Institute Inc. specializes in developing antibody therapeutics for cancer treatment, having been founded in 2016 in Tokyo, Japan.000 mn from Alfresa Holdings.000 mn.???????? specializes in the development of innovative antibody therapeutics aimed at enhancing cancer diagnosis and treatment. Their core product offerings include a range of proprietary monoclonal antibodies designed to target specific cancer cells, thereby improving both the efficacy and safety of cancer therapies. The products are intended to address critical challenges in oncology, such as late-stage diagnosis and limited treatment options for patients. The company aims to deliver these novel therapies to healthcare providers operating primarily within the Asian markets, focusing on regions with a growing demand for advanced cancer treatment options. Their client base consists of hospitals, oncology clinics, and research institutions that utilize these therapeutics to provide better outcomes for patients battling cancer.???????? generates revenue through strategic partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. The transaction structure typically involves licensing agreements and joint ventures, allowing the company to distribute its antibody products effectively within the oncology market. Revenue is derived from both upfront payments and milestone payments associated with the development and commercialization of their flagship antibody products. These arrangements are designed to foster long-term relationships with clients, ensuring a steady flow of income as the products advance through clinical trials and eventual market launch.In May 2023, RIN Institute Inc. The company plans to utilize these funds to further promote the ongoing Phase 1 study of its anti-TMEM180 antibody. They are focused on expanding their product pipeline and developing new antibody therapeutics, targeting enhanced market penetration in Asian regions with high demand for advanced oncology solutions.
Who invested in RIN Institute
2 investors across 2 rounds
See all investors in RIN Institute
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about RIN Institute
Who invested in RIN Institute?
RIN Institute has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RIN Institute raised?
RIN Institute has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did RIN Institute last raise money?
RIN Institute's most recent round on record is a Series B, in Dec 2020.
What does RIN Institute do?
Based in Japan, RIN Institute Inc.
Where is RIN Institute headquartered?
RIN Institute is headquartered in Tokyo, Japan.
Which VCs invest in companies like RIN Institute?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at RIN Institute's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like RIN Institute? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.